Integer Holdings (ITGR)
(Delayed Data from NYSE)
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
Zacks News
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
by Zacks Equity Research
Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
SenesTech's (SNES) New Partnership to Broaden Evolve's Scope
by Zacks Equity Research
The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.
PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.
Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.
DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.
Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio
by Zacks Equity Research
Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.
Illumina (ILMN) Extends Partnership to Advance Cancer Test
by Zacks Equity Research
Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.
Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence
by Zacks Equity Research
Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
by Zacks Equity Research
Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Microbot Medical (MBOT) Announces Positive GLP Study Results
by Zacks Equity Research
Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.